Improving Communication and Building a Stronger Medical Home Among Spanish-speaking Families

Sponsor
University of Colorado, Denver (Other)
Overall Status
Recruiting
CT.gov ID
NCT05425992
Collaborator
Children's Hospital Colorado (Other)
20
1
43.6
0.5

Study Details

Study Description

Brief Summary

This study will seek to improve communication with Spanish speaking families and patients with Cancer and Blood Disorders.

Condition or Disease Intervention/Treatment Phase
  • Other: Interview

Detailed Description

The Principal Investigator seeks to improve communication with Spanish speaking families with the following goals: 1) to increase patient and family sense of inclusion in the medical community, 2) to increase patient and family medical knowledge and understanding, 3) to improve patient adherence with critical medical regimens, and ultimately, 4) to increase equality of comprehensive medical care delivery across the continuum of care including physical and psychosocial domains.

Study Design

Study Type:
Observational
Anticipated Enrollment :
20 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Improving Communication With and Building a Stronger Medical Home Among Spanish-speaking Families in the Center for Cancer and Blood Disorders
Actual Study Start Date :
Mar 17, 2022
Anticipated Primary Completion Date :
Nov 4, 2023
Anticipated Study Completion Date :
Nov 4, 2025

Arms and Interventions

Arm Intervention/Treatment
Patients treated in CCBD

Patients who are currently receiving therapy at the Center for Cancer and Blood Disorders

Other: Interview
Patient/parent dyads expressing interest will be interviewed by a bilingual Spanish certified provider via televideo with as needed interpreter support. Interviews will be audio recorded for review and translation purposes and then will be destroyed. Interview format will be supportive and information seeking only with reassurance that purpose is for care improvement and that all answers will be evaluated without association to patient name. Interviews will then be translated and reviewed by the PI for themes regarding perceived clinic successes and perceived clinic barriers in communication or care.

Outcome Measures

Primary Outcome Measures

  1. Determine a baseline level of Spanish speaking patient satisfaction of care [12 months]

    Understand the patient experience using qualitative interview of Spanish speaking patients and families Determine satisfaction based on open-ended question with unsatisfied to satisfied as markers.

  2. Determine a baseline level of Spanish Speaking family satisfaction of care [12 months]

    Understand the patient experience using qualitative interview of Spanish speaking patients and families Determine satisfaction based on open-ended question with unsatisfied to satisfied as markers.

  3. Determine effects of language barrier on Spanish speaking patient needs [12 months]

    Understand the patient experience using qualitative interview of Spanish speaking patients and families. Determine satisfaction based on open-ended question to determine a list or pattern of common patient needs.

  4. Determine the effect of language barrier on barriers to patient care [12 months]

    Understand the patient experience using qualitative interview of Spanish speaking patients and families. Determine satisfaction based on open-ended question to determine a list or pattern of common barriers to patient care.

  5. Effect of language barrier on efficiency of access to care [12 months]

    Understand the patient experience using qualitative interview of Spanish speaking patients and families. Determine satisfaction based on open-ended question to determine how quickly patient was able to receive care.

Secondary Outcome Measures

  1. Determine patient interest in home telemedicine support program [12 months]

    Open-ended questions will be used to determine level of interest in a telemedicine support program.

  2. Determine patient interest in home telemedicine support program after discharge [12 months]

    Open-ended questions will be used to determine level of interest in a telemedicine support program to be used after discharge from hospital.

  3. Determine Spanish speaking patient interest in telemedical check-ins during intensive phases of therapy [12 months]

    Open-ended questions will be used to determine level of interest in a telemedical support during treatment.

  4. Determine Spanish speaking patient interest in medication assistance during intensive phases of therapy [12 months]

    Open-ended questions will be used to determine level of interest in a telemedical medication support during therapy.

  5. Determine Spanish speaking patient interest in medical check-ins during maintenance [12 months]

    Open-ended questions will be used to determine level of interest in a telemedical check-ins during maintenance.

  6. Determine Spanish speaking patient interest in medication assistance during maintenance [12 months]

    Open-ended questions will be used to determine level of interest in a telemedical medication assistance during maintenance.

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A to 22 Years
Sexes Eligible for Study:
All
Inclusion Criteria:
  • 0 to 22 years of age

  • Diagnosis of leukemia or non-Hodgkin lymphoma

  • Spanish as preferred language for patient, parent or guardian

  • Received or receiving care at the Center for Cancer and Blood Disorders (CCBD)

Exclusion Criteria:
  • Patients without oncologic diagnosis

  • Patients with parents whose language preference is English

  • Patients who received care solely outside of the CCBD

Contacts and Locations

Locations

Site City State Country Postal Code
1 Children's Hospital Colorado Aurora Colorado United States 80045

Sponsors and Collaborators

  • University of Colorado, Denver
  • Children's Hospital Colorado

Investigators

  • Principal Investigator: Ashley Rogers, Children's Hospital Colorado

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University of Colorado, Denver
ClinicalTrials.gov Identifier:
NCT05425992
Other Study ID Numbers:
  • 21-4238.cc
  • NCI-2022-04061
First Posted:
Jun 21, 2022
Last Update Posted:
Jun 21, 2022
Last Verified:
Jun 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by University of Colorado, Denver
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 21, 2022